KR102794727B1 - 클래스 ii, 유형 ii crispr 시스템 - Google Patents

클래스 ii, 유형 ii crispr 시스템 Download PDF

Info

Publication number
KR102794727B1
KR102794727B1 KR1020227037087A KR20227037087A KR102794727B1 KR 102794727 B1 KR102794727 B1 KR 102794727B1 KR 1020227037087 A KR1020227037087 A KR 1020227037087A KR 20227037087 A KR20227037087 A KR 20227037087A KR 102794727 B1 KR102794727 B1 KR 102794727B1
Authority
KR
South Korea
Prior art keywords
lys
arg
glu
leu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227037087A
Other languages
English (en)
Korean (ko)
Other versions
KR20220161383A (ko
Inventor
브라이언 토마스
크리스토퍼 브라운
오드라 디보토
크리스티나 버터필드
리사 알렉산더
다니엘라 에스 에이 골츠맨
Original Assignee
메타지노미, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메타지노미, 인크. filed Critical 메타지노미, 인크.
Priority to KR1020257011372A priority Critical patent/KR20250051161A/ko
Publication of KR20220161383A publication Critical patent/KR20220161383A/ko
Application granted granted Critical
Publication of KR102794727B1 publication Critical patent/KR102794727B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Confectionery (AREA)
  • Saccharide Compounds (AREA)
  • Seasonings (AREA)
KR1020227037087A 2020-03-31 2021-03-30 클래스 ii, 유형 ii crispr 시스템 Active KR102794727B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257011372A KR20250051161A (ko) 2020-03-31 2021-03-30 클래스 ii, 유형 ii crispr 시스템

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063003159P 2020-03-31 2020-03-31
US63/003,159 2020-03-31
US202063116149P 2020-11-19 2020-11-19
US63/116,149 2020-11-19
PCT/US2021/024945 WO2021202568A1 (en) 2020-03-31 2021-03-30 Class ii, type ii crispr systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257011372A Division KR20250051161A (ko) 2020-03-31 2021-03-30 클래스 ii, 유형 ii crispr 시스템

Publications (2)

Publication Number Publication Date
KR20220161383A KR20220161383A (ko) 2022-12-06
KR102794727B1 true KR102794727B1 (ko) 2025-04-11

Family

ID=77929138

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227037087A Active KR102794727B1 (ko) 2020-03-31 2021-03-30 클래스 ii, 유형 ii crispr 시스템
KR1020257011372A Pending KR20250051161A (ko) 2020-03-31 2021-03-30 클래스 ii, 유형 ii crispr 시스템

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257011372A Pending KR20250051161A (ko) 2020-03-31 2021-03-30 클래스 ii, 유형 ii crispr 시스템

Country Status (11)

Country Link
US (2) US11946039B2 (https=)
EP (2) EP4632066A3 (https=)
JP (2) JP7546689B2 (https=)
KR (2) KR102794727B1 (https=)
CN (1) CN116096877B (https=)
AU (1) AU2021248800A1 (https=)
CA (1) CA3177051A1 (https=)
ES (1) ES3055163T3 (https=)
GB (1) GB2608292B (https=)
MX (1) MX2022012110A (https=)
WO (1) WO2021202568A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US20220298494A1 (en) * 2019-02-14 2022-09-22 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
WO2021146641A1 (en) * 2020-01-17 2021-07-22 The Broad Institute, Inc. Small type ii-d cas proteins and methods of use thereof
WO2021202568A1 (en) 2020-03-31 2021-10-07 Metagenomi Ip Technologies, Llc Class ii, type ii crispr systems
JP2023540797A (ja) * 2020-09-11 2023-09-26 メタゲノミ，インコーポレイテッド 塩基編集酵素
AU2022335499A1 (en) 2021-08-27 2024-02-22 Metagenomi Therapeutics, Inc. Enzymes with ruvc domains
WO2023081855A1 (en) 2021-11-05 2023-05-11 Metagenomi, Inc. Base editing enzymes
EP4437095A1 (en) * 2021-11-24 2024-10-02 Metagenomi, Inc. Endonuclease systems
AU2022396533A1 (en) 2021-11-24 2024-05-02 Metagenomi Therapeutics, Inc. Endonuclease systems
ES2970263B2 (es) * 2022-10-21 2024-10-11 Univ Alicante PROTEINA ENDONUCLEASA Cas9 Y SISTEMA CRISPR-Cas ASOCIADO
AU2024236558A1 (en) 2023-03-15 2025-10-09 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
WO2024206759A1 (en) * 2023-03-31 2024-10-03 Arbor Biotechnologies, Inc. Crispr nuclease polypeptides and gene editing systems comprising such
CN121241133A (zh) * 2023-03-31 2025-12-30 阿伯生物技术公司 Crispr核酸酶多肽和包含此类crispr核酸酶多肽的基因编辑系统
WO2024206825A2 (en) * 2023-03-31 2024-10-03 Aera Therapeutics, Inc. Modified iscb nucleases, modified guide rnas, and uses thereof
WO2024233366A2 (en) * 2023-05-05 2024-11-14 Aera Therapeutics, Inc. Modified cas9-iid nucleases and uses thereof
EP4716752A2 (en) * 2023-05-23 2026-04-01 Metagenomi, Inc. Endonuclease systems
WO2025007044A1 (en) * 2023-06-28 2025-01-02 The University Of Chicago Methods and compositions comprising iscb variants
AU2024335327A1 (en) 2023-09-01 2026-03-26 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025054425A1 (en) * 2023-09-08 2025-03-13 Arbor Biotechnologies, Inc. Reverse transcription-mediated gene editing systems and uses thereof
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291438B1 (en) 1993-02-24 2001-09-18 Jui H. Wang Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
US5858988A (en) 1993-02-24 1999-01-12 Wang; Jui H. Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
US9637739B2 (en) * 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
PL3360964T3 (pl) 2012-12-06 2020-03-31 Sigma-Aldrich Co. Llc Modyfikacja i regulacja genomu oparta na crispr
WO2014093655A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
CN113355357B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
WO2015066119A1 (en) 2013-10-30 2015-05-07 North Carolina State University Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
EP4464338A3 (en) 2014-11-07 2025-02-12 Editas Medicine, Inc. Systems for improving crispr/cas-mediated genome-editing
KR20230156800A (ko) 2015-03-03 2023-11-14 더 제너럴 하스피탈 코포레이션 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제
AU2016263026A1 (en) 2015-05-15 2017-11-09 Pioneer Hi-Bred International, Inc. Guide RNA/Cas endonuclease systems
WO2016196655A1 (en) 2015-06-03 2016-12-08 The Regents Of The University Of California Cas9 variants and methods of use thereof
US20160362667A1 (en) 2015-06-10 2016-12-15 Caribou Biosciences, Inc. CRISPR-Cas Compositions and Methods
TWI906646B (zh) 2015-06-18 2025-12-01 美商博得學院股份有限公司 降低脫靶效應的ｃｒｉｓｐｒ酶突變
EP3426780A1 (en) 2016-03-11 2019-01-16 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
EP3500967A1 (en) 2016-08-17 2019-06-26 The Broad Institute, Inc. Methods for identifying class 2 crispr-cas systems
BR112019006388A2 (pt) * 2016-09-30 2019-06-25 Univ California enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas
SG10201913505WA (en) 2016-10-17 2020-02-27 Univ Nanyang Tech Truncated crispr-cas proteins for dna targeting
SG11201906297QA (en) 2017-03-24 2019-10-30 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof
EP3617311B1 (en) 2017-03-30 2024-11-20 Kyoto University Method for inducing exon skipping by genome editing
EP3625338A4 (en) 2017-05-19 2021-01-20 Tsinghua University CONSTRUCTION OF A MINIMAL SACAS9-CRISPR / CAS SYSTEM FOR GENEDITATION AND TRANSCRIPTION REGULATION, OPTIMIZED BY EXTENDED GUIDE-RNA
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
KR102465067B1 (ko) * 2018-02-15 2022-11-10 시그마-알드리치 컴퍼니., 엘엘씨 진핵 게놈 변형을 위한 조작된 cas9 시스템
WO2019165168A1 (en) 2018-02-23 2019-08-29 Pioneer Hi-Bred International, Inc. Novel cas9 orthologs
WO2020055941A1 (en) 2018-09-13 2020-03-19 Excision Biotherapeutics, Inc. Compositions and methods for excision with single grna
US20220298494A1 (en) 2019-02-14 2022-09-22 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
US20220220460A1 (en) 2019-02-14 2022-07-14 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
WO2021226363A1 (en) 2020-05-08 2021-11-11 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
CA3241703C (en) * 2019-02-14 2026-02-24 Metagenomi Therapeutics, Inc. Enzymes with ruvc domains
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
WO2021097118A1 (en) * 2019-11-12 2021-05-20 The Broad Institute, Inc. Small type ii cas proteins and methods of use thereof
WO2021202568A1 (en) 2020-03-31 2021-10-07 Metagenomi Ip Technologies, Llc Class ii, type ii crispr systems
WO2021202559A1 (en) * 2020-03-31 2021-10-07 Metagenomi Ip Technologies, Llc Class ii, type ii crispr systems
EP4165177A4 (en) 2020-05-08 2024-08-28 Metagenomi, Inc. ENZYMES WITH RUVC DOMAINS
JP2023540797A (ja) * 2020-09-11 2023-09-26 メタゲノミ，インコーポレイテッド 塩基編集酵素
CN116867897A (zh) * 2020-09-11 2023-10-10 宏基因组学公司 碱基编辑酶
JP2023546671A (ja) 2020-10-23 2023-11-07 ザ・ブロード・インスティテュート・インコーポレイテッド 再プログラム可能なｉｓｃｂヌクレアーゼ及びその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GenBank_OGP48943.1(2016.10.20.)*
Sergey Shmakov, et al, "Diversity and evolution of class 2 CRISPR-Cas system", Nature Reviews, vol 15(3), p169-182(2017.03.)*

Also Published As

Publication number Publication date
MX2022012110A (es) 2022-10-18
JP7546689B2 (ja) 2024-09-06
KR20220161383A (ko) 2022-12-06
CN116096877A (zh) 2023-05-09
US11946039B2 (en) 2024-04-02
KR20250051161A (ko) 2025-04-16
EP4127156B1 (en) 2025-09-10
ES3055163T3 (en) 2026-02-10
JP7785139B2 (ja) 2025-12-12
CN116096877B (zh) 2026-04-28
WO2021202568A1 (en) 2021-10-07
US20230051396A1 (en) 2023-02-16
JP2024178181A (ja) 2024-12-24
EP4632066A2 (en) 2025-10-15
AU2021248800A1 (en) 2022-10-13
GB202211839D0 (en) 2022-09-28
EP4127156C0 (en) 2025-09-10
GB2608292B (en) 2024-02-14
EP4127156A4 (en) 2024-03-27
GB2608292A (en) 2022-12-28
EP4127156A1 (en) 2023-02-08
CA3177051A1 (en) 2021-10-07
JP2023519953A (ja) 2023-05-15
EP4632066A3 (en) 2025-12-24
US20240309356A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
KR102794727B1 (ko) 클래스 ii, 유형 ii crispr 시스템
US12024727B2 (en) Enzymes with RuvC domains
US20240117330A1 (en) Enzymes with ruvc domains
JP7605852B2 (ja) クラスｉｉのｖ型ｃｒｉｓｐｒ系
US12410449B2 (en) Endonuclease systems
JP2025090617A (ja) Ｒｕｖｃドメインを有する酵素
EP4127155A1 (en) Class ii, type ii crispr systems
US20240409962A1 (en) Endonuclease systems
US20220220460A1 (en) Enzymes with ruvc domains
CN118265783A (zh) 核酸内切酶系统
HK40084708A (en) Class ii, type ii crispr systems
HK40084708B (en) Class ii, type ii crispr systems
GB2617659A (en) Enzymes with RUVC domains

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221025

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240710

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250108

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250408

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250408

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250408

End annual number: 3

Start annual number: 1

PG1601 Publication of registration